Doug Giordano is currently a Senior Vice President in Pfizer’s Worldwide Business Development Group, responsible for leading the evaluation, negotiation and execution of product licensing, partnerships and M&A transactions. Over the past six years, Doug has led teams responsible for Pfizer acquisitions and product licensing transactions including Pfizer’s acquisitions of Wyeth, Icagen, Excaliard, King Pharmaceuticals, FoldRx
, Coley, CovX, Encysive
, and product collaborations announced with various partners including Hisun, Mylan, GlycoMimetics, Bausch & Lomb and Teuto.
Before joining Pfizer’s Worldwide Business Development group in 2007, Doug held positions of increasing responsibility within Pfizer’s US Pharmaceuticals commercial strategy and business development team. Doug has been a key contributor to a variety of Pfizer transactions and a variety of innovative US commercialization initiatives including the creation and launch of the Pfizer/Microsoft/IBM collaboration, Amicore and the launch of the Pfizer for Living ShareCard and Pfizer Helpful Answers programs.
Before his US pharmaceuticals operating role, Doug worked in a mergers and acquisitions role within Pfizer’s Medical Technology Group -- playing a key role in Pfizer’s acquisitions, technology licensing and divestiture activity within medtech. Prior to his role with the Medical Technology Group, Doug held positions within Pfizer’s US Pharmaceutical Group in finance and global manufacturing.
Prior to joining Pfizer, Doug was a consultant at Booz, Allen & Hamilton.
Doug holds a Bachelor’s Degree in Biomedical Engineering from Duke University and an M.B.A. degree from Cornell University’s Johnson School of Business.